首页> 外文期刊>Diabetes >The Protective Effects of CD39 Overexpression in Multiple Low-Dose Streptozotocin-Induced Diabetes in Mice
【24h】

The Protective Effects of CD39 Overexpression in Multiple Low-Dose Streptozotocin-Induced Diabetes in Mice

机译:CD39过表达对多种低剂量链脲佐菌素诱发的糖尿病小鼠的保护作用

获取原文
获取原文并翻译 | 示例
       

摘要

Islet allograft survival limits the long-term success of islet transplantation as a potential curative therapy for type 1 diabetes. A number of factors compromise islet survival, including recurrent diabetes. We investigated whether CD39, an ectonucleo-tidase that promotes the generation of extracellular adenosine, would mitigate diabetes in the T cell-mediated multiple low-dose streptozotocin (MLDS) model. Mice null for CD39 (CD39KO), wild-type mice (WT), and mice overexpressing CD39 (CD39TG) were subjected to MLDS. Adoptive transfer experiments were performed to delineate the efficacy of tissue-restricted overexpression of CD39. The role of adenosine signaling was examined using mutant mice and pharmacological inhibition. The susceptibility to MLDS-induced diabetes was influenced by the level of expression of CD39. CD39KO mice developed diabetes more rapidly and with higher frequency than WT mice. In contrast, CD39TG mice were protected. CD39 overexpression conferred protection through the activation of adenosine 2A receptor and adenosine 2B receptor. Adoptive transfer experiments indicated that tissue-restricted overexpression of CD39 conferred robust protection, suggesting that this may be a useful strategy to protect islet grafts from T cell-mediated injury.
机译:胰岛同种异体移植的存活限制了胰岛移植作为1型糖尿病的潜在治疗方法的长期成功。许多因素会影响胰岛的生存,包括复发性糖尿病。我们研究了CD39,一种能促进细胞外腺苷生成的胞外核苷酸酶,是否可以减轻T细胞介导的多种低剂量链脲佐菌素(MLDS)模型中的糖尿病。将针对CD39(CD39KO),野生型小鼠(WT)和过表达CD39(CD39TG)的小鼠无效的小鼠进行MLDS。进行过继转移实验以描述组织限制的CD39过表达的功效。使用突变小鼠和药理学抑制作用检查了腺苷信号传导的作用。 MLDS诱导的糖尿病易感性受CD39表达水平的影响。与WT小鼠相比,CD39KO小鼠患糖尿病的速度更快,频率更高。相反,CD39TG小鼠受到保护。 CD39过表达通过激活腺苷2A受体和腺苷2B受体赋予保护作用。过继转移实验表明,CD39的组织限制性过表达赋予了强有力的保护,表明这可能是保护胰岛移植物免受T细胞介导的损伤的有用策略。

著录项

  • 来源
    《Diabetes》 |2013年第6期|2026-2035|共10页
  • 作者单位

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia,Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia;

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia;

    St Vincent's Institute, Fitzroy, Victoria, Australia;

    St Vincent's Institute, Fitzroy, Victoria, Australia;

    St Vincent's Institute, Fitzroy, Victoria, Australia;

    Department of Pathology, St. Vincent's Hospital, Melbourne, Victoria, Australia;

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia;

    Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts;

    Molecular Neuropharmacology Laboratory, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts;

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia,Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia;

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia,Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia;

    Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia,Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:25

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号